Skip to main content

Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress

Current TAP Partner


BERKELEY, Calif., Dec. 12, 2022 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported new 12-month clinical data from cohort 1 in the ongoing ANTLER Phase 1 trial, which show long-term durability following a single infusion of CB-010 at the initial dose level 1 (40x106 CAR-T cells). Cohort 1 results show:

  • 6 of 6 patients achieved a complete response (CR) as best response
  • 3 of 6 patients maintained a durable CR at 6 months
  • 2 of 6 patients maintain a long-term CR at the 12 month scan and remain on the trial
  • 18 months is the longest CR maintained to date in ANTLER, achieved by the first patient dosed with CB-010
  • CB-010 was generally well tolerated with adverse events consistent with autologous or allogeneic anti-CD19 CAR-T cell therapies

Based on promising initial data, the U.S. Food and Drug Administration (FDA) granted CB-010 both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. In addition, Caribou has observed an encouraging safety profile for CB-010 at dose level 2 (80x106 CAR-T cells) with no dose-limiting toxicities (DLTs) in the 3 patients treated and is currently enrolling patients at dose level 3 (120x106 CAR-T cells). Caribou expects to provide an ANTLER trial update in 2023.

ANTLER Trial-in-Progress Poster at ASH 2022
Today at the 64th Annual ASH meeting, a trial-in-progress poster is being presented to provide details of the design and objectives of the ANTLER Phase 1 trial for CB-010 in r/r B-NHL. Details of the poster presentation are as follows:

Title: A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)
Presenter: Susan O’Brien, M.D., professor of medicine, Chao Family Comprehensive Cancer Center at University of California, Irvine, CA
Session Name: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III
Session Date: Monday, December 12, 2022
Presentation Time: 6:00 pm - 8:00 pm CST
Location: Ernest N. Morial Convention Center, Hall D
Abstract number: 4257

Press Release